48 research outputs found
The role of immunophenotyping in differential diagnosis of chronic lymphocytic leukemia
Introduction. Accurate diagnosis of chronic lymphocytic leukemia (CLL)
acquires immunophenotyping by flow cytometry in order to facilitate
differential diagnosis between CLL and other mature B-cell neoplasms (MBCN).
Objective. The aim of this study was to define immunological profile of CLL
cells. Methods. Immunophenotyping by flow cytometry was performed on
peripheral blood specimens at diagnosis in the group of 211 patients with de
novo MBCN. Results. Absolute count of B-cells was significantly increased in
all MBCN patients comparing to healthy control group (p<0.05). B-cell
monoclonality was detected in 96% of all MBCN patients, by using surface
immunoglobulin (sIg) light chain restriction. B-cell antigens, CD19, CD20,
CD22, were expressed with very high frequency in CLL and other MBCN. In
comparison with other MBCN, in CLL group, the frequency of expression was
higher for CD5 and CD23 (p<0.0001), though lower for FMC7 antigen (p<0.0001).
CLL patients were characterized by lower expression patterns of CD20, CD22,
CD79b, and sIg (p<0.0001) as well as higher expression pattern of CD5 antigen
(p<0.05). Correlation between the final diagnosis of MBCN and values of CLL
scoring system showed that the majority of CLL patients (97%) had higher
values (5 or 4) whereas the majority of other MBCN patients (96%) had lower
score values (0-3). Conclusion. Our results have shown that characteristic
immunophenotype which differentiates CLL from other MBCN is defined by
following marker combination - CD19+ CD20+low CD22+low CD5+high CD23+ FMC7-
CD79b+low sIg+low. CLL score values of 5 or 4 points are highly suggestive
for diagnosis of CLL
Double-hit primary unilateral adrenal lymphoma with good outcome
Introduction. Primary adrenal non-Hodgkinās lymphoma (NHL) is a rare neoplasm
with poor prognosis. On the other side, double-hit lymphomas with BCL2 and
MYC translocation are characterized by advanced disease stage, extranodal and
central nervous system involvements at presentation or disease progression.
Case report. We reported a 73-year-old male patient with double-hit primary
adrenal lymphoma and preserved adrenal function, showing a favorable clinical
course. Computed tomography of abdomen showed a 9 7 cm mass of the left
adrenal gland. Laparatomy with left adrenalectomy was done and histological
examination revealed diagnosis of a diffuse large B-cell NHL (DLBCL), non-GCB
subtype. The patient was treated with 6 cycles of R-CHOP chemotherapy with
reduced doses of doxorubicin because of the decreased left verticle ejection
fraction. The patient was followed up regularly for 20 months with no
evidence of tumor recurrence despite the inherently poor prognostic profile
and double-hit phenotype of the disease. Conclusion. R-CHOP chemotherapy in
combination with adrenalectomy can be an effective first-line regimen for
primary adrenal DLBCL, despite the inherently poor prognostic profile
(non-GCB subtype, bulky disease, elevated lactate dehydrogenase and
double-hit phenotype of the disease)
Extramedullary plasmacytoma of the tongue base: A rare presentation of head and neck plasmacytoma
Introduction. Special entities like solitary bone plasmocytoma (SBP) or extramedullary plasmacytoma (EMP) can be found in a less than 5% of patients with plasma cell disorders. EMP of the tongue represents very rare localization of the head and neck plasmacytoma. Case report. We report a case of 78-years-old woman who developed EMP of the tongue base detected by the magnetic resonance imaging (MRI) of the head and neck region. Immunohistochemical profile of the tumor tissue biopsy (CD38, IgG, kappa positivity) indicated diagnosis of EMP. The diagnosis was established with additional staging which confirmed the absence of other manifestation of the disease. The patient was treated with 40 Gy of radiotherapy in 20 doses resulting in the achievement of the complete remission of the disease. This case was discussed with the reference to the literature. Conclusion. EMP of the tongue base is a very rare entity of plasma cell dyscrasias. Appropriate irradiation results in the achievement of a long-term remission and a potential cure of the disease
Predictors of Vancomycin-Resistant Enterococcus spp. Intestinal Carriage among High-Risk Patients in University Hospitals in Serbia
The predictors of intestinal carriage of vancomycin-resistant Enterococcus spp. (VRE) among high-risk patients in the counties of the Southeast Europe Region are insufficiently investigated, yet they could be of key importance in infection control. The aim of the study was to identify risk factors associated with fecal VRE colonization among high-risk inpatients in university hospitals in Serbia. The study comprised 268 inpatients from three university hospitals. Data on patient demographics and clinical characteristics, length of hospital stay, therapy, and procedures were obtained from medical records. Chi-squared tests and univariate and multivariate logistic regressions were performed. Compared to the hemodialysis departments, stay in the geriatric departments, ICUs, and haemato-oncology departments increased the risk for VRE colonization 7.6, 5.4, and 5.5 times, respectively. Compared to inpatients who were hospitalized 48 h before stool sampling for VRE isolation, inpatients hospitalized 3ā7, 8ā15, and longer than 16 days before sampling had 5.0-, 4.7-, and 6.6-fold higher risk for VRE colonization, respectively. The use of cephalosporins and fluoroquinolones increased the risk for VRE colonization by 2.2 and 1.9 times, respectively. The age ā„ 65 years increased the risk for VRE colonization 2.3 times. In comparison to the University Clinical Centre of Serbia, the hospital stays at Zemun and Zvezdara University Medical Centres were identified as a protector factors. The obtained results could be valuable in predicting the fecal VRE colonization status at patient admission and consequent implementation of infection control measures targeting at-risk inpatients where VRE screening is not routinely performed
Clinical significance of TP53 aberrations and IGHV mutational status in chronic lymphocytic leukemia
HroniÄna limfocitna leukemija (HLL) izuzetno je heterogena bolest varijabilnog kliniÄkog toka. S jedne strane imamo, pacijente sa agresivnom i rezistentnom boleÅ”Äu od koje umiru svega par meseci nakon dijagnoze, dok s druge strane spektra postoje pacijenti sa indolentnom, sporo progredirajuÄom boleÅ”Äu koja ne zahteva leÄenje decenijama. Razlozi su samo delimiÄno poznati i veÄ su decenijama unazad tema mnogobrojnih nauÄnih istraživanja. Tako je razvijen koncept prognostiÄkih i prediktivnih faktora u HLL-u, koji imaju za cilj da predvide kliniÄki tok, odnosno terapijski ishod HLL-a. Liste prognostiÄkih i prediktivnih faktora su, sa boljim poznavanjem patofiziologije ove bolesti, svakom godinom sve duže, ali se i meÄusobno preklapaju. U ovom revijalnom radu izabrali smo aberacije TP53 gena i mutacioni status rearanžiranih IGHV (engl. immunoglobulin heavy variable) gena kao dva najznaÄajnija i najprouÄavanija faktora koji imaju i prognostiÄki i prediktivni znaÄaj.Chronic lymphocytic leukemia (CLL) is a very heterogeneous disease with a variable clinical course. On the one side of the spectrum, there are patients with aggressive and resistant disease, of which they die only a few months after diagnosis while, on the other side, there are patients with an indolent, slowly progressive disease that does not require treatment for decades. The reasons for this are only partially known, but they have been the subject of numerous scientific studies during the last several decades. Consequently, the concept of prognostic and predictive factors in CLL have emerged, which aims to predict the clinical course and its therapeutic outcome. With the improvement of understanding the pathophysiology of this disease, the lists of prognostic and predictive factors are getting longer every year, but they also overlap. In this review, we singled out the aberrations of the TP53 gene and the IGHV (immunoglobulin heavy variable) gene mutational status as the two most important and most studied factors that have both prognostic and predictive significance
Influence of applied CD34+ cell dose on the survival of Hodgkin's lymphoma and multiple myeloma patients following autologous stem cell transplants
Background/Aim. Autologous stem cell transplants (ASCTs) improve the rate of overall survival (OS) in patients with hematological malignancies such as multiple myeloma (MM) after induction chemotherapy, aggressive non-Hodgkin's lymphomas (NHL), and relapsed, chemotherapy-sensitive Hodgkin's lymphoma (HL). The study aim was to evaluate influence of applied CD34+ cell quantity on clinical outcome, as well as early post-transplant and overall survival (OS) of HL and MM patients following ASCT. Methods. This study included a total of 210 patients (90 HL/120 MM) who underwent ASCT. Stem cell (SC) mobilization was accomplished by granulocyte-colony stimulating factor (G-CSF) 10ā16 Ī¼g/kg body mass (bm) following chemotherapy. For proven poor mobilizers, mobilization with G-CSF (16 Ī¼g/kgbm) and Plerixafor (24 or 48 mg) was performed. To our best knowledge, it was the first usage of the Plerixafor in our country in the ASCT-setting. Harvesting was initiated merely at "cut-off-value" of CD34+ cells ā„ 20 Ć 106/L in peripheral blood with "target-dose" of CD34+ cells ā„ 5 Ć 106/kgbm in harvest. The CD34+ cell count and viability was determined using flow cytometry. Results. The majority of HL patients (76.7%) were infused with > 5.0 Ć 106/kgbm CD34+ cells, while 68.3% of MM patients were treated by approximately 4.0ā5.4 Ć 106/kgbm CD34+ dose, respectively. Beneficial response (complete/partial remission) was achieved in 83.3% (HL) and 94.2% (MM) patients. Among parameters that influenced survival of HL patients with positive response to the therapy, multivariate analysis (pre-ASCT performance status, CD34+ cell quantity applied, rapid hematopoietic, i.e. lymphocyte and platelet recovery) indicated that higher CD34+ cell dose used, along with pre-ASCT performance status correlated with superior event-free survival (EFS) and OS following ASCT. In MM patients, multivariate analysis (renal impairment, infused CD34+ cell quantity, early platelet recovery) indicated that the number of CD34+ cells infused was the most important parameter that influenced both EFS and OS after ASCT. Conclusion. Data obtained in this study undoubtedly confirmed that CD34+ cell dose applied is an independent factor that may contribute to superior clinical outcome and OS of HL and MM patients following ASCT
CytomegalovirusĀ infectionĀ mayĀ be oncoprotectiveĀ against neoplasms of B-lymphocyte lineage: single-institution experience and survey of global evidence
Although cytomegalovirus (CMV) is not considered tumorigenic, there is evidence for its oncomodulatory effects and association with hematological neoplasms. Conversely, a number of experimental and clinical studies suggest its putative anti-tumour effect. We investigated the potential connection between chronic CMV infection in patients with B-lymphocyte (B-cell) malignancies in a retrospective single-center study and extracted relevant data on CMV prevalences and the incidences of B-cell cancers the world over
Electroconvulsive therapy: eighty years of Croatian and international experience
Elektrokonvulzivna terapija (EKT) i nakon viÅ”e od 80 godina primjene i dalje predstavlja najuÄinkovitiju terapiju kod najtežih kliniÄkih slika psihijatrijskih poremeÄaja. U Hrvatskoj se EKT primjenjuje od 40-ih godina proÅ”log stoljeÄa. Danas se koristi samo u KBC-u Zagreb, najÄeÅ”Äe u pacijenata sa shizofrenijom. Brojna istraživanja su utvrdila razliÄite bioloÅ”ke uÄinke EKT-a koji pridonose antidepresivnom, antimaniÄnom, antipsihotiÄnom, antikonvulzivnom i antiparkinsonskom uÄinku. Konvulzije imaju snažan uÄinak na perfuziju i metabolizam pojedinih moždanih regija, poveÄanje propusnosti krvnomoždane barijere te imaju modulatorni uÄinak na glutamatnu, GABA, serotoninsku, dopaminsku i noradrenergiÄku neurotransmisiju, hormonalnu sekreciju, promjene u ekspresiji brojnih gena te potiÄu neuroplastiÄnost i u konaÄnici dovode do strukturnih promjena mozga. Neke su od ovih promjena kratkog vijeka, a neke traju mjesecima, poput neuroplastiÄnosti. Iako se EKT smatra medicinskim postupkom niskog rizika, mnoge teÅ”ke somatske bolesti zahtijevaju pažljivu procjenu koristi i rizika. NajÄeÅ”Äe su neželjene reakcije prolazne teÅ”koÄe pamÄenja i glavobolja. Prije prve aplikacije kandidati prolaze detaljnu dijagnostiÄku obradu u skladu s meÄunarodnim standardima. U postupku primjene EKT-a sudjeluje interdisciplinarni tim koji ukljuÄuje psihijatra, anesteziologa, anestezioloÅ”ku sestru/tehniÄara i psihijatrijsku sestru/tehniÄara. Primjena opÄe anestezije omoguÄuje brz gubitak svijesti, kratkotrajnu miÅ”iÄnu relaksaciju, smanjenje hiperdinamskog odgovora na elektriÄnu stimulaciju te brz oporavak spontane ventilacije i svijesti. Nedavno su predložene Hrvatske nacionalne smjernice o primjeni EKT-a. Zbog uÄinka u terapijskoj rezistenciji te kod vrlo teÅ”kih kliniÄkih slika EKT može ostvariti znaÄajan uÄinak u pažljivo odabranih bolesnika.Electroconvulsive therapy (ECT), even more than 80 years since its introduction, continues to be the most effective treatment for severe mental disorders. Croatian psychiatrists have used ECT since 1940s. Today it is performed only at the University Hospital Centre Zagreb, predominantly in patients with schizophrenia. Extensive research reported numerous biological effects of ECT, which contribute to its antidepressant, antimanic, antipsychotic, anticonvulsive and antiparkinsonian effects. Convulsions trigger changes in the cerebral blood flow and metabolism, increase the permeability of the blood-brain barrier, modulate glutamatergic, GABAergic, serotonergic, noradrenergic and dopaminergic neurotransmission, affect hormone secretion, gene expression, stimulate neuroplasticity, and eventually induce brain structural changes. Some of these effects are short-lasting and others,
such a neuroplasticity, last for at least several months. While ECT is generally considered a low-risk medical treatment, patients with severe somatic comorbidity require careful risk-benefit assessment. The most commonly observed adverse events are transient forgetfulness and headache. Prior to initiation, candidates undergo comprehensive diagnostic evaluation according to international standards. The procedure is performed by an interdisciplinary team, consisting of psychiatrist, anesthesiologist, and psychiatric and anesthesiological nurses. The application of general anesthesia enables rapid loss of consciousness, short-time muscular relaxation, suppression of hyperdynamic response to electrical current and fast recovery of breathing and awareness. Recently, the Croatian expert group has proposed national guidelines for the ECT treatment. Due to its efficacy in both treatment-refractory and very severe symptomatology, ECT might be of a great benefit in carefully selected patients
Comparative analysis of International Prognostic Index for chronic lymphocytic leukemia, progression-risk score, and MD Anderson Cancer Center 2011 score: A single center experience
Uvod/Cilj Prognoza hroniÄne limfocitne leukemije (HLL) znaÄajno je unapreÄena u poslednje vreme. MeÄu nekoliko prognostiÄkih modela Äiji je cilj predviÄanje vremena do prve terapije (eng. TTFT) izdvajaju se skor rizika od progresije (eng. PRS) i skor Centra za rak MD Anderson iz 2011. God. (eng. MDACC 2011), dok se internacionalni prognostiÄki indeks za HLL (eng. CLL-IPI), iako primarno ustanovljen za predikciju ukupnog preživljavanja (eng. OS), dobro pokazao i u predikciji TTFT. Cilj ovog rada je da se ispita znaÄaj pomenutih prognostiÄkih modela u pogledu predviÄanja TTFT i OS. Metode Analizirana kohorta je obuhvatila 57 neselektovanih bolesnika sa HLL Univerzitetskog kliniÄkog centra Srbije sa proseÄno agresivnijim profilom bolesti u odnosu na opÅ”tu populaciju de novo bolesnika sa HLL. Bolesnici su ocenjivani prema navedenim skorovima uz analizu TTFT i OS. Rezultati Bolesnici sa viÅ”im vrednostima CLL-IPI, PRS i MDACC 2011 primili su prvu terapiju znaÄajno ranije u poreÄenju sa bolesnicima sa nižim vrednostima ovih skorova (p = 0,002, p = 0,019 i p lt 0,001, redom). U multivarijantnoj analizi, MDACC 2011 i CLL-IPI su zadržali prognostiÄki znaÄaj u predikciji TTFT (p = 0,001, odnosno p = 0,018), dok je PRS ovaj znaÄaj izgubio. CLL-IPI je bio jedini znaÄajan prediktor OS u univarijantnoj (p = 0,005) i u multivarijantnoj analizi (p = 0,013). ZakljuÄak CLL-IPI, PRS i naroÄito MDACC 2011 su dobri prediktori TTFT Äak i u kohortama bolesnika sa agresivnijom boleÅ”Äu, dok je za predikciju OS od ova tri prognostiÄka modela CLL-IPI jedini primenljiv. Ovi rezultati pokazuju da bi prognostiÄke modele trebalo ispitati na bolesnicima sa HLL u razliÄitim fazama bolesti, kakvi se sreÄu u realnoj kliniÄkoj praksi.Introduction/Objective Prognostication of chronic lymphocytic leukemia (CLL) has been substantially improved in recent times. Among several prognostic models (PMs) focused on the prediction of time to first treatment (TTFT), progression-risk score (PRS), and MD Anderson Cancer Center score 2011 (MDACC 2011) are the most relevant, while CLL-International Prognostic Index (CLL-IPI), although originally developed to predict overall survival (OS), is also being used to estimate TTFT. The aim of this study was to investigate CLL-IPI, PRS, and MDACC 2011 prognostic values regarding TTFT and OS. Methods The analyzed cohort included 57 unselected Serbian CLL patients from a single institution, with the basic characteristics reflecting more aggressive disease than in the general de novo CLL population. The eligible patients were assigned investigated PMs, and TTFT and OS analyses were performed. Results Patients with higher risk scores according to CLL-IPI, PRS, and MDACC 2011 underwent treatment significantly earlier than patients with lower risk scores (p = 0.002, p = 0.019, and p lt 0.001, respectively). In multivariate analysis, MDACC 2011 and CLL-IPI retained their significance regarding TTFT (p = 0.001 and p = 0.018, respectively), while PRS did not. CLL-IPI was the only significant predictor of OS both at the univariate (p = 0.005) and multivariate (p = 0.013) levels. Conclusion CLL-IPI, PRS, and particularly MDACC 2011 are able to predict TTFT even in cohorts with more advanced-disease patients, while for prediction of OS, CLL-IPI is the only applicable among the three PMs. These results imply that PMs should be investigated in more diverse CLL populations, as it is in real-life setting